-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

Benzinga·11/13/2025 11:00:59
Listen to the news
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.